A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding...

Area of Science:

• Cardiology
• Hematology
• Anesthesiology

Background:

• Bleeding after cardiac surgery is a significant complication associated with increased mortality.
• Conventional therapies may be insufficient for refractory bleeding, leading to off-label use of factor concentrates.
• Four-factor prothrombin complex concentrate (PCC) and recombinant activated factor VII (rFVIIa) are used in such cases.

Purpose of the Study:

• To assess and compare the hemostatic effectiveness and safety of 4-factor PCC versus rFVIIa.
• To evaluate outcomes in patients undergoing cardiac surgery with refractory bleeding treated with either 4-factor PCC or rFVIIa.

Main Methods:

• Retrospective study including adult patients who underwent cardiac surgery and required intervention with 4-factor PCC or rFVIIa for bleeding.
• Comparison of transfusion requirements (packed red blood cells, fresh frozen plasma, platelets, cryoprecipitate), chest tube output, reexploration rates, ICU length of stay, and 30-day thromboembolic complications.
• Analysis of total drug dosage administered for both treatment groups.

Main Results:

• No significant differences were observed in packed red blood cell or platelet transfusions between the 4-factor PCC and rFVIIa groups.
• The rFVIIa group required more cryoprecipitate than the 4-factor PCC group (p = 0.03).
• Thromboembolic complications at 30 days were similar (13% for 4-factor PCC vs. 26% for rFVIIa, p = 0.08), with no differences in secondary outcomes like chest tube output, reexploration rates, or ICU length of stay.

Conclusions:

• Both 4-factor PCC and rFVIIa appear to be safe and effective options for managing bleeding after cardiac surgery.
• The study demonstrates the feasibility of using minimum drug dosages to achieve desired hemostatic effects.
• Further research may be warranted to optimize the use of these factor concentrates in cardiac surgery.